logo
Plus   Neg
Share
Email

Dr. Reddy's Laboratories Enters Licensing Deal With Gilead Sciences For Remdesivir

Dr. Reddy's Laboratories Ltd. (RDY) announced that it has entered licensing deal with Gilead Sciences, Inc. (GILD) to register, manufacture and sell Gilead's antiviral drug Remdesivir for the treatment of COVID-19, in 127 countries including India.

Under non-exclusive licensing agreement, Dr. Reddy's will receive technology transfer from Gilead for manufacturing of Remdesivir. Dr. Reddy's would need to do manufacturing scale up and obtain regulatory approval for marketing of Remdesivir in respective countries.

In May, FDA has issued emergency use authorization for Gilead Science Inc's (GILD) antiviral drug Remdesivir to treat Covid-19.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Santa Cruz Bicycles LLC has recalled certain model year 2020 bicycles with aluminum frames citing fall risks, according to the U.S. Consumer Product Safety Commission. The recall involves about 2,900 units of model year 2020 Auminum Santa Cruz and Juliana Bicycles. In addition, about 216 were sold in Canada. AstraZeneca is mulling an additional global trial to confirm the 90% efficacy rate of its Covid-19 vaccine candidate at lower dosage, Bloomberg news quoted Chief Executive Officer Pascal Soriot as saying. In an interview, Soriot noted that instead of adding the trial to an ongoing U.S. process, the company might launch a fresh study to evaluate efficacy of lower dosage of its vaccine that perform U.S. airline Delta Air Lines, Inc. and its Italian codeshare partner Alitalia are planning to launch quarantine-free, COVID-free flights between U.S. and Europe through new testing protocols, starting in December. In a statement, Delta said it has signed deals with airports and governments eliminating quarantine requirements on COVID-tested flights connecting Atlanta and Rome.
Follow RTT